Patent: 9,643,980
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,643,980
Title: | Benzoxazepin oxazolidinone compounds and methods of use |
Abstract: | Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. |
Inventor(s): | Braun; Marie-Gabrielle (South San Francisco, CA), Hanan; Emily (Redwood City, CA), Staben; Steven T. (San Francisco, CA), Heald; Robert Andrew (Sawbridgeworth, GB), MacLeod; Calum (Harlow Essex, GB), Elliott; Richard (Harlow Essex, GB) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 15/200,307 |
Patent Claims: | see list of patent claims |
Details for Patent 9,643,980
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |